• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Aeterna Zentaris Inc.

    6/13/24 9:20:29 AM ET
    $AEZS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEZS alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2024

     

    Commission File Number: 001-38064

     

    Aeterna Zentaris Inc.

    (Translation of registrant’s name into English)

     

    c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

     

     

     

     
     

     

     

    Exhibit 99.1, included with this report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834) and Forms F-3 (No.333-232935 and No. 333-254680) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    DOCUMENTS INDEX

     

    Exhibit   Description
    99.1   Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

     

    (2)
     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        AETERNA ZENTARIS INC.
           
    Date: June 13, 2024   By: /s/ Gilles Gagnon
          Gilles Gagnon
          President and Chief Executive Officer

     

    (3)

     

    Get the next $AEZS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AEZS

    DatePrice TargetRatingAnalyst
    10/25/2021$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEZS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

      TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ:AEZS) (TSX:AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company's name has been changed from "Aeterna Zentaris Inc." to "COSCIENS Biopharma Inc.", effective as of August 6, 2024 (the "Name Change"). In addition, the Company announces that, effective as of August 9, 2024, the Company's common shares (the "Common Shares") will begin trading on the Toronto Stock

      8/6/24 6:00:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

      TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of NomineeVotes For% ForVotes Against% AgainstRon

      7/16/24 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $AEZS
    SEC Filings

    See more
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

      8/13/24 8:05:36 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)

      8/13/24 8:05:17 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Aeterna Zentaris Inc.

      6-K - Aeterna Zentaris Inc. (0001113423) (Filer)

      8/6/24 6:22:58 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEZS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on AEterna Zentaris with a new price target

      HC Wainwright & Co. initiated coverage of AEterna Zentaris with a rating of Buy and set a new price target of $2.00

      10/25/21 6:23:09 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEZS
    Leadership Updates

    Live Leadership Updates

    See more
    • Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

      TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today. Results of the AGSM The results of the vote in respect of the election of directors of the Company are set out below: Name of NomineeVotes For% ForVotes Against% AgainstRon

      7/16/24 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

      – Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors TORONTO, ONTARIO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the appointment of Giuliano La Fratta as Senior Vice President, Chief Financial Officer. Effective January 24th, 2022, Mr. La Fratta will be responsible for the finance-related leadership functions, succeeding Ms. Leslie Auld, the Company's current Senior Vice President,

      12/23/21 4:05:00 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEZS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aeterna Zentaris Inc.

      SC 13G - Aeterna Zentaris Inc. (0001113423) (Subject)

      6/6/24 1:46:51 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aeterna Zentaris Inc. (Amendment)

      SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)

      2/11/22 6:41:14 AM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Aeterna Zentaris Inc. (0001113423) (Subject)

      2/16/21 2:50:58 PM ET
      $AEZS
      Biotechnology: Pharmaceutical Preparations
      Health Care